ReviewFrontiers in cell and developmental biology2026
Citrus flavanones (naringenin, hesperidin, and hesperetin) in oral and gastric carcinogenesis: mechanistic insights into oxidative stress, cell death, epigenetic regulation, non-coding RNAs, and tumor microenvironment remodeling.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flavonoids derived from citrus fruits, including naringenin, naringin, hesperetin, and hesperidin, represent a class of dietary bioactives with potential chemopreventive properties against oral cancer and gastric cancer (GC). However, previous reviews have largely focused on isolated molecular pathways or single cancer types, lacking an integrated comparison of oral and gastric carcinogenesis within a unified mechanistic framework. Preclinical investigations using chemical carcinogenesis models consistently show that these compounds attenuate oxidative stress, restore cellular redox balance, and modulate critical regulators of tumor progression through interconnected redox-sensitive signaling pathways. Nanoparticle-based delivery enhances bioavailability, tissue targeting, and pharmacokinetics, amplifying their therapeutic efficacy. In oral carcinoma models, flavonoids suppress tumor growth and enhance chemosensitivity, whereas in GC they inhibit malignant progression and metastatic behavior. Additionally, these compounds influence the tumor microenvironment (TME) by modulating immune surveillance, suppressing PD-L1 expression, restraining angiogenesis, and interacting with microbial and inflammatory pathways. Epigenetic and non-coding RNA mechanisms, including DNA methylation, microRNA, and long non-coding RNA regulation, further contribute to their anticancer activity. Unlike previous reports, this review integrates intracellular signaling, TME modulation, epigenetic regulation, and nanodelivery strategies across both oral and GC models, providing a unified multi-layered mechanistic framework. Collectively, these findings delineate a multi-layered mechanistic framework for citrus flavonoids, supporting their promise as adjunctive chemopreventive agents while emphasizing the necessity for translational and clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.